Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 219

Sort by

Sort Order Select

Journal Articles

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Kavitha Godugu, PhD, Shymaa Mousa, Noureldien Hassan Elsayed Darwish, MDPhDBS, Shaker A Mousa, PhD BPharm, MBA, MSc

Blood (2019) 134 (Supplement_1): 3670.

https://doi.org/10.1182/blood-2019-130992

Published: 2019

Journal Articles

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Pável E Olivera, MD, César A Velasquez, MD, Desirée Campoy, MD, Gonzalo Artaza, MD, Tania Canals, MD, Katia Flores, MD, Silvia Ruiz, MD, Alessandra Comai, MD, Erik A Johansson, MD, Gabriela S Ene, MD PhD, Gabriela Bastidas, MD, Maricel Subira, MD PhD, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 3661.

https://doi.org/10.1182/blood-2019-128300

Published: 2019

Journal Articles

Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects

Nausheen Baig, Ahmed Kouta, Fakiha Siddiqui, Ambar Farooqui, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Cassie Bacher, Sharan Krishnappan, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3665.

https://doi.org/10.1182/blood-2019-126075

Published: 2019

Journal Articles

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Debra Hoppensteadt, PhD, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, MD, Walter Jeske, PhD, Jeanine Walenga, PhD, Alfonso J Tafur, MD MS, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3374.

https://doi.org/10.1182/blood-2019-131221

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels

Ahmed Kouta, Walter Jeske, PhD, Rick Duff, Debra Hoppensteadt, PhD, Omer Iqbal, MD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 165.

https://doi.org/10.1182/blood-2019-131943

Published: 2019

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Factor XII Deficiency in ECMO Patients

Katherine Regling, DO, Sarah Ramiz, MD, Meera B. Chitlur, MD

Blood (2019) 134 (Supplement_1): 4965.

https://doi.org/10.1182/blood-2019-131614

Published: 2019

Journal Articles

Comparison of Low Molecular Weight Heparin Activity Assays with and without Addition of Exogenous Antithrombin in a Pediatric and Young Adult Leukemia Cohort

Beverly Schaefer, MD, Adriane Hausfeld, Paul Steele, MD, Jan Martin, Sandra Brannon, Adam Lane, PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4915.

https://doi.org/10.1182/blood-2019-123716

Published: 2019

Journal Articles

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Shveta Gupta, MBBS, Ayesha Zia, MD, Ravindra Sarode, MD

Blood (2019) 134 (Supplement_1): 4976.

https://doi.org/10.1182/blood-2019-129118

Published: 2019

Journal Articles

Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes

Anny Appert-Flory, MD, Florence Fischer, MD, Didier Jambou, MD, Sylvain Buvat, Marie-Helene Mahagne, MD, Pierre Toulon, MD

Blood (2019) 134 (Supplement_1): 3403.

https://doi.org/10.1182/blood-2019-130533

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Siddharth Mehrotra, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Omer Iqbal, MD, Alfonso J Tafur, MD MS, Bruce Lewis, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1155.

https://doi.org/10.1182/blood-2019-131907

Published: 2019

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Saurabh Gombar, MD PhD, Derek Boothroyd, PhD, Anandi Krishnan, PhD, Husham Sharifi, MD, Joe Hsu, MD, James Zehnder, MD

Blood (2019) 134 (Supplement_1): 712.

https://doi.org/10.1182/blood-2019-132112

Published: 2019

Journal Articles

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Beverley J. Hunt, Matthew D. Neal, Jakob Stensballe

Blood (2018) 132 (23): 2441–2445.

https://doi.org/10.1182/blood-2018-06-850396

Published: 2018

Journal Articles

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Fakiha Siddiqui, Siddharth Mehrotra, Vishnu Venkitasubramony, Rithik Raina, Lorenzo Storino Ramacciotti, Jack Bontekoe, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Walter Jeske, PhD, Jawed Fareed, PhD

Blood (2018) 132 (Supplement 1): 2520.

https://doi.org/10.1182/blood-2018-99-116993

Published: 2018

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Kamila I. Cisak, MD, Dennis Asante, MS, Diane E. Grill, MS, Aneel A. Ashrani, MD, M.S.

Blood (2018) 132 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2018-99-117607

Published: 2018

NARROW

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Factor XII Deficiency in ECMO Patients

Comparison of Low Molecular Weight Heparin Activity Assays with and without Addition of Exogenous Antithrombin in a Pediatric and Young Adult Leukemia Cohort

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Monitoring Unfractionated Heparin Treatments. Stability of Plasma Anti-Xa Activity up to 4 Hours in Citrated Tubes

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Reversing anti–factor Xa agents and the unmet needs in trauma patients

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only